Theoretical Uncertainties in Electroweak Boson Production Cross Sections at 7, 10, and 14 TeV at the LHC

We present an updated study of the systematic errors in the measurements of the electroweak boson cross-sections at the LHC for various experimental cuts for a center of mass energy of 7, 10 and 14 TeV. The size of both electroweak and NNLO QCD contributions are estimated, together with the systematic error from the parton distributions. The effects of new versions of the MSTW, CTEQ, and NNPDF PDFs are considered.Comment: PDFLatex with JHEP3.cls. 22 pages, 43 figures. Version 2 adds the CT10W PDF set to analysis and updates the final systematic error table and conclusions, plus several citations and minor wording changes. Version 3 adds some references on electroweak and mixed QED/QCD corrections. Version 4 adds more references and acknowledgement

Biowire model of interstitial and focal cardiac fibrosis

Myocardial fibrosis is a severe global health problem due to its prevalence in all forms of cardiac diseases and direct role in causing heart failure. The discovery of efficient antifibrotic compounds has been hampered due to the lack of a physiologically relevant disease model. Herein, we present a disease model of human myocardial fibrosis and use it to establish a compound screening system. In the Biowire II platform, cardiac tissues are suspended between a pair of poly(octamethylene maleate (anhydride) citrate) (POMaC) wires. Noninvasive functional readouts are realized on the basis of the deflection of the intrinsically fluorescent polymer. The disease model is constructed to recapitulate contractile, biomechanical, and electrophysiological complexities of fibrotic myocardium. Additionally, we constructed a heteropolar integrated model with fibrotic and healthy cardiac tissues coupled together. The integrated model captures the regional heterogeneity of scar lesion, border zone, and adjacent healthy myocardium. Finally, we demonstrate the utility of the system for the evaluation of antifibrotic compounds. The high-fidelity in vitro model system combined with convenient functional readouts could potentially facilitate the development of precision medicine strategies for cardiac fibrosis modeling and establish a pipeline for preclinical compound screening